Treatment of facial lipoatrophy via autologous fat transfer

Journal of Drugs in Dermatology

Volumn 8, Issue 5, 2009, Pages 486-489

  Cohen, George ^a   Treherne, Annyce ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADRENALIN PLUS LIDOCAINE; ALCOHOL; ANTICOAGULANT AGENT; POVIDONE IODINE; SODIUM CHLORIDE;

ABDOMINAL SUBCUTANEOUS FAT; ANTISEPSIS; ARTICLE; AUTOLOGOUS FAT TRANSFER; AUTOTRANSPLANTATION; CENTRIFUGATION; DONOR SELECTION; DONOR SITE; DRUG HYPERSENSITIVITY; DRUG USE; FACIAL LIPOATROPHY; HEART DISEASE; INFECTION; INFORMED CONSENT; LABORATORY TEST; LIPOATROPHY; MEDICAL HISTORY; MEDICAL PHOTOGRAPHY; MINIMALLY INVASIVE SURGERY; NEEDLE; NERVE BLOCK; PATIENT EDUCATION; PATIENT POSITIONING; PATIENT SELECTION; PHYSICAL EXAMINATION; PREOPERATIVE EVALUATION; RESPIRATORY TRACT DISEASE; SURGICAL RISK; SUTURE; SYMPTOMATOLOGY; SYRINGE; VASOCONSTRICTION; ADIPOSE TISSUE; CHEMICALLY INDUCED DISORDER; ESTHETIC SURGERY; FACE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV ASSOCIATED LIPODYSTROPHY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; TRANSPLANTATION;

ADIPOSE TISSUE; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COSMETIC TECHNIQUES; FACE; HIV INFECTIONS; HIV-1; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; TISSUE AND ORGAN HARVESTING; TRANSPLANTATION, AUTOLOGOUS;

EID: 67649846475     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Carr A, Cooper DA. Adverse effects of antiretroviral therapy. Lancet. 2000;356(9239):1423-1430.
2. Sherman R. Autologous fat transfer for lipodystrophy. Cosmetic Dermatol. 2006;16:34-45.
3. Coleman SR. Long-term survival of fat transplants: Controlled demonstrations. Aesthetic Plast Surg. 1995;19(5):421-425.
4. Fontdevila J, et al. Clinical classification of facial atrophy in HIV infected patients. Antiviral Ther. 2003; 8: L81
5. Bisaccia E, Scarborough DA, Ara C, et al. Exploring the options for treating perioral signs of aging. Skin & Aging. 2003;11:58-71.
6. Valentin MA, Aubron-Oliver C, Ghosn J, et al. Polylactic acid implants (New-Fill) to correct facial lipoatrophy in HIV infected patients results of the open label study VEGA. AIDS. 2003; 17(17):2471-2477. (Pubitemid 38393319)
7. Engelhard P, Humble G, Mest D. Safet of Sculptra: A review of clinical trial data. J Cosmet Laser Ther. 2005;7(3-4):201-205. (Pubitemid 43111922)
8. Narins R, Brandt F, Leyden J, et al. A randomized, double blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the correction of nasolabial folds. Dermatol Surg. 2003;29(6):588-595. (Pubitemid 36702442)
9. Bugge H. Hyaluronic Acid treatment of facial fat atrophy in HIVpositive patients. HIV Med. 2007;8(8):475-482. (Pubitemid 47616825)
10. Goldberg DJ. Calcium Hydoxylapatite. Fillers in Cosmetic Dermatology. Abingdon, England: Informa UK Ltd., 2006.
11. Jansen DA and Graivier MH. Evaluation of calcium hydroxypatite-based implant (Radiesse) for facial soft tissue augmentation. Plast Reconstr Surg. 118(Suppl.):22S,2006.
12. Comite SL, Liu JF, Balasubramanian S, Christian MA. Treatment of HIV-associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J. 2004;10(2):2.
13. Burres S. Fascian. Facial Plast Surg. 2004;20(2):149-152.
14. Jones D. HIV Facial lipoatrophy: Etiology and methods of correction. In: Klein AW, editor. Tissue augmentation in clinical practice: Procedures and techniques. New York: Marcel Dekker; 2006.